Nexalin Technology Inc. designs and develops neurostimulation products for mental health epidemic. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. Nexalin Technology Inc. is based in Houston, Texas.
Revenue (Most Recent Fiscal Year) | $0.11M |
Net Income (Most Recent Fiscal Year) | $-4.65M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 95.07 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.29 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -4197.82% |
Net Margin (Trailing 12 Months) | -4185.46% |
Return on Equity (Trailing 12 Months) | -122.57% |
Return on Assets (Trailing 12 Months) | -97.00% |
Current Ratio (Most Recent Fiscal Quarter) | 8.07 |
Quick Ratio (Most Recent Fiscal Quarter) | 7.70 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | 0.16 |
Book Value per Share (Most Recent Fiscal Quarter) | $0.43 |
Earnings per Share (Most Recent Fiscal Quarter) | -- |
Earnings per Share (Most Recent Fiscal Year) | -- |
Diluted Earnings per Share (Trailing 12 Months) | -- |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Medical Devices |
Common Shares Outstanding | 7.44M |
Free Float | 5.38M |
Market Capitalization | $10.56M |
Average Volume (Last 20 Days) | 1.55M |
Beta (Past 60 Months) | 6.34 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 27.69% |
Percentage Held By Institutions (Latest 13F Reports) | 0.65% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |